Form D · Biotechnology
KAZIA THERAPEUTICS LTD
Sydney Nsw, C3 · CIK 0001075880
Offering snapshot reported Dec 18, 2025 · SEC filing
- Reported sold
- $55.3M Offering amount: $55.3M
- Investors reported
- 65 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 3, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 18, 2025 | Initial | $55,251,088 | No comparison | 65 | SEC filing |
| Aug 14, 2025 | Initial | $2,050,013 | No comparison | 4 | SEC filing |
| Jan 17, 2025 | Initial | $2,060,000 | No comparison | 1 | SEC filing |
| Dec 15, 2023 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.33M
- Finders' fees
- $0
- Form D file number
- 021-567348
Includes pre-funded warrants for 938,490 ADSs, each representing 500 ordinary shares, and their aggregate exercise price at $0.0001 per ADS; and aggregate exercise price of warrants to placement agent for 700,013 ADSs at exercise price $7.5 per ADS.
The amount reflects placement agent fee of up to 7% of the gross proceeds. In addition, placement agent also received warrants to purchase up to 700,013 ADSs at an exercise price of $7.50 per ADSs.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| T.R. Winston & Company LLC | 10571 | Konik Capital Partners LLC |
Source: Form D, filed Dec 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Apple | Director |
| Jeffrey Bonacorda | Executive |
| Bryce Carmine | Director |
| Steven Coffey | Director |
| Ebru Davidson | Director |
| John Friend | Executive |
| Elissa Hansen | Executive |
| Karen Krumeich | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Three International Towers Level 24, 300 Barangaroo Avenue
Sydney Nsw, C3, 2000
Sydney Nsw, C3, 2000